July 26th 2024
SenoVax, a novel senolytic immunotherapy for NSCLC, has been submitted as an investigational new drug application to the FDA, initiating a clinical trial to test its efficacy.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Selpercatinib Improves Survival vs Chemotherapy in RET+ NSCLC
October 21st 2023Results phase 3 LIBRETTO-431 trial presented at the 2023 ESMO Congress showed selpercatinib monotherapy demonstrated better survival results than chemotherapy with or without pembrolizumab for patients with RET fusion–positive non–small cell lung cancer.
Read More
In ALK+ NSCLC Alectinib Reduces Disease Risks in Early-Stage Setting
October 21st 2023Results from the phase 3 ALINA trial showed the benefit of ALK inhibition for patients with ALK-positive, early-stage, non–small-cell lung cancer with use of adjuvant alectinib significantly improving disease-free survival.
Read More
Addition of Adjuvant Nivolumab Improves EFS in NSCLC
October 21st 2023In the first phase 3 perioperative study of patients with resectable non–small cell lung cancer given adjuvant nivolumab after surgery and a prior regimen of nivolumab and chemotherapy showed improved event-free survival results.
Read More
Managing Adverse Events in EGFR Exon 20 Insertion–Targeted Therapies for NSCLC
October 20th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Millie S. Das, MD, and participants discussed considerations for managing toxicities of amivantamab and mobocertinib for patients with EGFR exon 20 insertion–positive non–small cell lung cancer.
Read More
Riess Reviews Pivotal Trials for Nonmetastatic Lung Cancer
October 19th 2023During a Targeted Oncology™ Clinical Case Forum event in partnership with the Nevada Oncology Society, Jonathan Riess, MD, MS, summarized the outcomes and impact of the PACIFIC and ADAURA trials in patients with nonmetastatic non–small cell lung cancer.
Read More
Nivolumab/Chemotherapy Regimen Shows EFS Benefits in NSCLC
October 18th 2023Neoadjuvant nivolumab and chemotherapy followed by surgery and adjuvant nivolumab demonstrated improvements in event-free survival, pathologic complete response, and major pathologic response in non–small cell lung cancer.
Read More
Behind the FDA Approval of Neoadjuvant/Adjuvant Pembrolizumab in NSCLC
October 17th 2023In an interview with Targeted Oncology, Heather Wakelee, MD, discussed what community oncologists should know about the newly approved combination of pembrolizumab with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of pembrolizumab monotherapy as post-surgical adjuvant treatment.
Read More
Bright Future of Lung Cancer Research: Targeted Therapies and Immunotherapy Advancements
October 16th 2023Expert Sandip Patel, MD, looks toward the promising future of lung cancer research, including targeted therapies, novel immunotherapy approaches, and the importance of biomarkers in guiding treatment decisions.
Watch
Tailoring Lung Cancer Treatment: Balancing Immunotherapy, Chemotherapy, and Targeted Therapies
October 16th 2023Insight into key patient characteristics and considerations in determining the optimal approach for treating metastatic non-small cell lung cancer, including the role of chemotherapy, immunotherapy, and targeted therapy.
Watch
Randomized Trial Provides Biomarker and CNS Sotorasib Data in NSCLC
October 4th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Timothy F. Burns, MD, PhD, discussed the results of the phase 3 CodeBreaK 200 trial in patients with KRAS G12C-positive lung cancer. This is the second article based on this event.
Read More
Stereotactic Radiosurgery Plus Immunotherapy, Safe for Metastatic NSCLC
October 2nd 2023A recent phase 1/2 study revealed promising results, with an estimated 4-month intracranial progression-free survival rate of 70.7% with stereotactic radiosurgery with the combination of nivolumab and ipilimumab.
Read More
Case Overview: A 62-Year-Old Woman with Squamous Histology and PD-L1 Negative mNSCLC
September 29th 2023Expert oncologist Sandip Patel, MD, discusses treatment decisions for a 62-year-old female with squamous cell lung cancer, highlighting the use of CTLA4 and PD1 inhibitors based on subgroup analysis.
Watch
Identifying the Role of Targeted Therapy in KRAS-Mutated NSCLC
September 26th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Timothy F. Burns, MD, PhD, discussed the use of sotorasib and adagrasib for patients with KRAS-mutated non–small cell lung cancer including those with brain metastases.
Read More